Published in Chest on June 01, 2013
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis (2015) 0.81
Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype. Cough (2014) 0.81
Content validity of CASA-Q cough domains and UCSD-SOBQ for use in patients with Idiopathic Pulmonary Fibrosis. Glob J Health Sci (2013) 0.79
Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis (2016) 0.76
Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Curr Respir Med Rev (2016) 0.75
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain (2001) 16.05
The St George's Respiratory Questionnaire. Respir Med (1991) 8.49
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med (1998) 6.22
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol (2003) 5.16
Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol (1999) 4.90
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med (2001) 4.39
Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care (1999) 3.57
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med (2012) 2.36
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
The estimation of intraclass correlation in the analysis of family data. Biometrics (1980) 2.06
Evaluation of a cough-specific quality-of-life questionnaire. Chest (2002) 1.89
Assessing health status and quality of life in idiopathic pulmonary fibrosis: which measure should be used? Respir Med (2000) 1.73
Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med (2005) 1.51
A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.07
Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines. Chest (2006) 0.96
Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology (2011) 0.95
A prospective global measure, the Punum Ladder, provides more valid assessments of quality of life than a retrospective transition measure. J Clin Epidemiol (2010) 0.89
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev (2011) 0.85
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22
Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74
Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol (2006) 3.32
Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Pediatric self-management: a framework for research, practice, and policy. Pediatrics (2012) 1.63
A clinician's guide to the diagnosis and treatment of interstitial lung diseases. South Med J (2007) 1.43
Nighttime caregiving behaviors among parents of young children with Type 1 diabetes: associations with illness characteristics and parent functioning. Fam Syst Health (2009) 1.23
Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med (2009) 1.15
Sleep quality and health-related quality of life in idiopathic pulmonary fibrosis. Chest (2008) 1.09
Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res (2005) 1.09
The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol (2004) 1.08
Stress among fathers of young children with type 1 diabetes. Fam Syst Health (2009) 1.08
Advanced visualization of airways with 64-MDCT: 3D mapping and virtual bronchoscopy. AJR Am J Roentgenol (2007) 1.07
Supporting parents of very young children with type 1 diabetes: results from a pilot study. Patient Educ Couns (2011) 1.01
Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med (2011) 1.00
Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription. J Immunol (2006) 0.98
Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs (2014) 0.96
Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression. J Inflamm (Lond) (2008) 0.96
Differential regulation of hyaluronan-induced IL-8 and IP-10 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2006) 0.96
The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion. Am J Respir Cell Mol Biol (2008) 0.95
Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Pulm Circ (2012) 0.94
Individual and family strengths: an examination of the relation to disease management and metabolic control in youth with type 1 diabetes. Fam Syst Health (2011) 0.93
Pulmonary vaccination as a novel treatment for lung fibrosis. PLoS One (2012) 0.91
Hyaluronan fragments induce IFNβ via a novel TLR4-TRIF-TBK1-IRF3-dependent pathway. J Inflamm (Lond) (2013) 0.89
Source of biomass cooking fuel determines pulmonary response to household air pollution. Am J Respir Cell Mol Biol (2014) 0.84
Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor. Am J Respir Cell Mol Biol (2011) 0.83
Identification of the molecular mechanism by which TLR ligation and IFN-gamma synergize to induce MIG. Clin Dev Immunol (2004) 0.82
An Fc domain protein-small molecule conjugate as an enhanced immunomodulator. J Am Chem Soc (2014) 0.80
Regulation of CD4⁺ and CD8⁺ effector responses by Sprouty-1. PLoS One (2012) 0.78
Motivational interviewing to promote adherence behaviors in pediatric type 1 diabetes. Curr Diab Rep (2014) 0.78
Author reply: To PMID 22986377. Ann Intern Med (2013) 0.75
Respiratory CSI: diagnosing occupationally related lung disease. South Med J (2008) 0.75
Practical strategies to enhance executive functioning and strengthen diabetes management across the lifespan. Curr Diab Rep (2015) 0.75
Correction: Immunological Priming Requires Regulatory T Cells and IL-10-Producing Macrophages To Accelerate Resolution from Severe Lung Inflammation. J Immunol (2016) 0.75
Caregiver depression and perceptions of primary care predict clinic attendance in head start children with asthma. J Asthma (2014) 0.75